Loading...
 
Mediterr J Rheumatol 2019;30(Supp 1):59-62
SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience
Authors Information

Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

References
  1. Dörner T, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J. et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016;75:974-82. [https://doi.org/10.1136/annrheumdis-2016-209166] [PMID: 26964144] [PMCID: PMC4893105]
  2. Mohler KM, Torrance DS, Smith CA, Goodwin RC, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61. [PMID: 8393046]
  3. Chadwick L, Zhao SZ, Mysler E, Moots RJ. Review of biosimilar trials and data on etanercept in rheumatoid arthritis. Curr Rheumatol Rep 2018;20:84. [https://doi.org/10.1007/s11926-018-0799-0] [PMID: 30411183] [PMCID: PMC6244902]
  4. Norman P. Enbrel and etanercept biosimilars: a tale of two patent systems. Pharm Pat Anal 2017;6:5-7. [https://doi.org/10.4155/ppa-2016-0043] [PMID: 28201948]
  5. Lee YJ, Shin D, Kim Y, Kang JW, Fuhr R, Gauliard A. SAT0176 A Phase I Pharmacokinetic Study Comparing SB4, An Etanercept Biosimilar, and Etanercept Reference Product (Enbrel®) in Healthy Male Subjects. Ann Rheum Dis 2015;74(Suppl2):718.1-718. [https://doi.org/10.1136/annrheumdis-2015-eular.2671]
  6. Moots R, Azevedo V, Coindreau JL, Dorner T, Mahgoub E. Mysler E. et al. Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. Curr Rheumatol Reports 2017;19:37. [https://doi.org/10.1007/s11926-017-0658-4] [PMID: 28623625] [PMCID: PMC5486595]
  7. Emery P, Vencovsky J, Sylwestrzak A, Leszczyński P, Porawska W, Baranauskaite A,et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017;76:51-7. [https://doi.org/10.1136/annrheumdis-2015-207588] [PMID: 26150601] [PMCID: PMC5264222]
  8. Emery P, Vencovsky J, Sylwestrzak A, Leszczyński P, Porawska W, Stasiuk B, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis 2017;76:1986-91. [https://doi.org/10.1136/annrheumdis-2017-211591] [PMID: 28794078] [PMCID: PMC5705842]
  9. Vencovsky J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, Tseluyko V, et al. A2055 A Phase III, Randomized, Double-Blind Clinical Study Comparing SB4, an Etanercept Biosimilar, with Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (52-week Results). Arthritis Rheumatol 2015;67(Suppl 10).
  10. Scheinberg M, Azevedo V. Difference between Enbrel and Benepali treatment groups in ‘hepatobiliary disorders’. Ann Rheum Dis 2016;75:E64-E. [https://doi.org/10.1136/annrheumdis-2016-210101] [PMID: 27432354]
  11. Emery P, Vencovsky J, Sylwestrzak A, Leszczyñski P, Porawska W, Stasiuk B,et al. A603 Additional Efficacy Results of SB4 (Etanercept Biosimilar) up to Week 100: Comparison Between Continuing SB4 and Switching from Reference Etanercept (Enbrel®) to SB4. Arthritis Rheum 2016;68(suppl 10).
  12. Tweehuysen L, Huiskes VJB, van den Bemt BJF, Vriezekolk JE, Teerenstra S, van den Hoogen FHJ, et al. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4 Six-Month Results From a Controlled Cohort Study. Arthritis Rheum 2018;70:1408-18. [https://doi.org/10.1002/art.40516] [PMID: 29609207]
  13. De Cock D, Kearsley-Fleet L, Davies R, Watson K, Hyrich KL. A2539 SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care. Arthritis Rheumatol 2018;70(suppl 10).
  14. Holroyd C, Wallis D, Bennett S, Clayton P, Edwards CJ. AB0377 Switching from bio-original etanercept to biosimilar etanercept sb4: patient acceptability and outcomes in the real world. Ann Rheum Dis 2017;76:1180. [https://doi.org/10.1136/annrheumdis-2017-eular.3672]
  15. Sigurdardottir V, Husmark T, Svard A. SAT0173 Switching from reference product etanercept to the biosimilar sb4 in a real-life setting: follow-up of 147 patients. Ann Rheum Dis 2017;76:835.
  16. Kruger K, Selmi C, Cantagrel A, Abad MA, Freudensprung U, Rezk MF, et al. A2537 Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA). Arthritis Rheum 2018;70 (suppl 10).
  17. Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis 2017;76:4-6. [https://doi.org/10.1136/annrheumdis-2015-208113] [PMID: 27566795]